Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Drops By 99.4%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large drop in short interest in August. As of August 14th, there was short interest totaling 26,461 shares, a drop of 99.4% from the July 30th total of 4,613,535 shares. Based on an average daily trading volume, of 2,740,460 shares, the days-to-cover ratio is currently 0.0 days. Approximately 5.8% of the company’s shares are sold short.

China SXT Pharmaceuticals Stock Down 0.6%

China SXT Pharmaceuticals stock opened at $3.56 on Thursday. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $99.22 and a two-hundred day moving average of $136.01. China SXT Pharmaceuticals has a one year low of $3.10 and a one year high of $83,758.80.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share (EPS) for the quarter. The company had revenue of $0.26 million during the quarter.

Wall Street Analyst Weigh In

SXTC has been the subject of several research reports. Weiss Ratings upgraded China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC increased its stake in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares in the last quarter. Citadel Advisors LLC acquired a new position in China SXT Pharmaceuticals in the 3rd quarter worth about $78,000. Finally, XTX Topco Ltd purchased a new position in China SXT Pharmaceuticals during the fourth quarter worth approximately $36,000. 5.02% of the stock is owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.